Culture morphology, source-tissue/PDO H&E and hepatocyte- and endothelial-related IHC guide efficacy and mechanism endpoints in liver-cancer studies.
STUDY EVIDENCE
Culture morphology, histology and immunohistochemistry establish model context and guide endpoint selection for follow-on efficacy and mechanism studies.
PDO culture morphology is evaluated with source-tissue/PDO H&E and endothelial- and hepatocyte-related IHC to connect culture, tissue structure and lineage context.
Guides model and endpoint selection for efficacy and mechanism studies
Bright-field and whole-mount immunofluorescence in a conventional HCC PDO document morphology and cell state, adding a complementary conventional-PDO view to liver-cancer study design.
Adds conventional-PDO morphology and cell-state contextINTERPRETATION
Defines efficacy or mechanism study directions for the profiled liver-tumor samples.
Interpret results in the context of sample pathology, tissue source, culture morphology and markers, then use them to design efficacy and mechanism studies.
Build pathology- and target-informed dose, time-course and additional-sample studies.
Related models and services
PROJECT DISCUSSION
Tell us which model features and readouts matter most. Our scientists will recommend the model, QC plan and study endpoints.
Culture morphology, source-tissue/PDO H&E and hepatocyte- and endothelial-related IHC guide efficacy and mechanism endpoints in liver-cancer studies.
STUDY EVIDENCE
Culture morphology, histology and immunohistochemistry establish model context and guide endpoint selection for follow-on efficacy and mechanism studies.
PDO culture morphology is evaluated with source-tissue/PDO H&E and endothelial- and hepatocyte-related IHC to connect culture, tissue structure and lineage context.
Guides model and endpoint selection for efficacy and mechanism studiesBright-field and whole-mount immunofluorescence in a conventional HCC PDO document morphology and cell state, adding a complementary conventional-PDO view to liver-cancer study design.
Adds conventional-PDO morphology and cell-state contextINTERPRETATION
Defines efficacy or mechanism study directions for the profiled liver-tumor samples.
Interpret results in the context of sample pathology, tissue source, culture morphology and markers, then use them to design efficacy and mechanism studies.
Build pathology- and target-informed dose, time-course and additional-sample studies.
Related models and services
PROJECT DISCUSSION
Tell us which model features and readouts matter most. Our scientists will recommend the model, QC plan and study endpoints.
